Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty

Yoichi Nakamura, Kazufumi Nakamura, Keiko Ohta, Hiromi Matsubara, Chikao Yutani, Tsutomu Hamuro, Hisao Kato, Tohru Ohe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. Methods: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon™. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 μg of rTFPI given at 40 μg per pulse per minute by means of a Pulse Spray™ catheter. Thereafter, 34 rabbits which had received 200 μg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. Results: A total of 2.6 ± 1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. Conclusions: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.

Original languageEnglish
Pages (from-to)198-205
Number of pages8
JournalBasic Research in Cardiology
Volume97
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Balloon Angioplasty
Anti-Inflammatory Agents
Thrombosis
Rabbits
lipoprotein-associated coagulation inhibitor
Iliac Artery
Angioplasty
Smooth Muscle Myocytes
Half-Life
Pulse
Catheters

Keywords

  • Angioplasty
  • Arteries
  • Inflammation
  • Restenosis
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. / Nakamura, Yoichi; Nakamura, Kazufumi; Ohta, Keiko; Matsubara, Hiromi; Yutani, Chikao; Hamuro, Tsutomu; Kato, Hisao; Ohe, Tohru.

In: Basic Research in Cardiology, Vol. 97, No. 3, 2002, p. 198-205.

Research output: Contribution to journalArticle

Nakamura, Yoichi ; Nakamura, Kazufumi ; Ohta, Keiko ; Matsubara, Hiromi ; Yutani, Chikao ; Hamuro, Tsutomu ; Kato, Hisao ; Ohe, Tohru. / Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. In: Basic Research in Cardiology. 2002 ; Vol. 97, No. 3. pp. 198-205.
@article{473da7b7e57445b191a2f98fbfedd38a,
title = "Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty",
abstract = "Background: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. Methods: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon™. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 μg of rTFPI given at 40 μg per pulse per minute by means of a Pulse Spray™ catheter. Thereafter, 34 rabbits which had received 200 μg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. Results: A total of 2.6 ± 1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 {\%} of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. Conclusions: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.",
keywords = "Angioplasty, Arteries, Inflammation, Restenosis, Thrombosis",
author = "Yoichi Nakamura and Kazufumi Nakamura and Keiko Ohta and Hiromi Matsubara and Chikao Yutani and Tsutomu Hamuro and Hisao Kato and Tohru Ohe",
year = "2002",
doi = "10.1007/s003950200012",
language = "English",
volume = "97",
pages = "198--205",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

TY - JOUR

T1 - Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty

AU - Nakamura, Yoichi

AU - Nakamura, Kazufumi

AU - Ohta, Keiko

AU - Matsubara, Hiromi

AU - Yutani, Chikao

AU - Hamuro, Tsutomu

AU - Kato, Hisao

AU - Ohe, Tohru

PY - 2002

Y1 - 2002

N2 - Background: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. Methods: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon™. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 μg of rTFPI given at 40 μg per pulse per minute by means of a Pulse Spray™ catheter. Thereafter, 34 rabbits which had received 200 μg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. Results: A total of 2.6 ± 1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. Conclusions: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.

AB - Background: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. Methods: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon™. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 μg of rTFPI given at 40 μg per pulse per minute by means of a Pulse Spray™ catheter. Thereafter, 34 rabbits which had received 200 μg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. Results: A total of 2.6 ± 1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. Conclusions: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.

KW - Angioplasty

KW - Arteries

KW - Inflammation

KW - Restenosis

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0036247999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036247999&partnerID=8YFLogxK

U2 - 10.1007/s003950200012

DO - 10.1007/s003950200012

M3 - Article

C2 - 12061389

AN - SCOPUS:0036247999

VL - 97

SP - 198

EP - 205

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 3

ER -